Log in or Sign up for Free to view tailored content for your specialty!
HF/Transplantation News
SGLT2 inhibitors greatly underprescribed in patients who qualify for them
In an analysis of more than 3 million U.S. adults, most patients with a class 1a recommendation for SGLT2 inhibitors were not prescribed them, researchers reported in the Journal of the American College of Cardiology.
FDA approves expanded indication of furosemide injection for NYHA class IV heart failure
scPharmaceuticals Inc. announced the FDA approved the supplemental new drug application to expand the indication of its self-administered subcutaneous furosemide injection for patients with heart failure.
Log in or Sign up for Free to view tailored content for your specialty!
Air pollution exposure linked to higher risk for adverse outcomes among patients with HF
Ambient air pollution was associated with an increased risk for adverse events among Medicare beneficiaries with preexisting HF, according to a study published in the Journal of the American Heart Association.
Q&A: Stanford Children’s heart transplant patients ‘not just surviving but thriving’
Stanford Medicine Children’s Health this year celebrated 50 years of pediatric heart transplants and more than 35 years of pediatric lung transplants, according to a press release.
Q&A: New class of total artificial heart implanted successfully for first time
The first implantation of a new class of total artificial heart, a rotary pump with a single moving part, was successfully completed by a team at The Texas Heart Institute, the institution reported.
Follow-up care after CV hospitalization rising, but not for some groups
Overall rates of postdischarge follow-up care after heart disease hospitalization has increased, but gaps in follow-up care for Black and Medicaid dual-eligible patients widened, researchers reported.
Revisions to allocation policy did not lower pediatric heart transplant waitlist mortality
The 2016 revisions to the United Network for Organ Sharing pediatric heart transplant allocation policy were not independently associated with a drop in waitlist mortality, researchers reported.
Top-line results: Finerenone reduces events in certain patients with heart failure
Bayer announced positive top-line results for the FINEARTS-HF trial of finerenone, in which the drug reduced risk for cardiovascular death and heart failure events in patients with HF with preserved or mildly reduced ejection fraction.
Top-line data suggest improved outcomes, symptoms with tirzepatide for HFpEF and obesity
Tirzepatide significantly reduced HF outcomes and symptoms for patients with HF and preserved ejection fraction and obesity, according to the top-line results of the phase 3 SUMMIT clinical trial.
Mental health ‘crucial’ after first-time hospitalization for heart disease
Risk for psychiatric disorder or suicide attempt is particularly high in the first year following hospitalization for heart disease, and patient support is important to lower such risk, researchers reported.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read